IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis

Trials

E. Lord¹  M. Thursz¹  N. Vergis¹  N. Foster¹  R. Goldin¹  E. Forrest²  J. Czyzewska-Khan³  F. Fiorentino³  E. Day³  M. Cross³  K. Bogdanowicz³  V. Patel⁴ 

[1] Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK;Glasgow Royal Infirmary and University of Glasgow, Glasgow, UK;Imperial Clinical Trials Unit, Department of Surgery and Cancer, Imperial College, London, UK;Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London, UK;Institute of Hepatology London, Foundation for Liver Research, London, UK;School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK;

关键词: Alcoholic hepatitis;    Interleukin 1β;    Canakinumab;   

DOI  :  10.1186/s13063-021-05719-2

来源: Springer

【 摘 要 】

BackgroundAlcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this study is to explore the potential benefits of the IL-1β antibody, canakinumab, in the treatment of AH.MethodsThis is a multicentre, double-blind, randomised placebo-controlled trial. Participants will be diagnosed with AH using clinical criteria. Liver biopsy will then confirm that all histological features of AH are present. Up to 58 participants will be recruited into two groups from 15 centres in the UK. Patients will receive an infusion of Canakinumab or matched placebo by random 1:1 allocation. The primary outcome is the difference between groups in the proportion of patients demonstrating histological improvement and will compare histological appearances at baseline with appearances at 28 days to assign a category of “improved” or “not improved”. Patients with evidence of ongoing disease activity will receive a second infusion of canakinumab or placebo. Participants will be followed up for 90 days. Secondary outcomes include mortality and change in MELD score at 90 days.DiscussionThis phase II study will explore the benefits of the IL-1β antibody, canakinumab, in the treatment of AH to provide proof of concept that inhibition of IL-1β signalling may improve histology and survival for patients with AH.Trial registrationEudraCT 2017-003724-79. Prospectively registered on 13 April 2018.

【 授权许可】

CC BY